NRG BN002: SAFETY DATA FROM A PHASE I STUDY OF IPILIMUMAB (IPI), NIVOLUMAB (NIVO), AND THE COMBINATION FOR NEWLY DIAGNOSED GLIOBLASTOMA (GBM) Conference

Gilbert, Mark, Zhang, Peixin, Sloan, Andrew et al. (2018). NRG BN002: SAFETY DATA FROM A PHASE I STUDY OF IPILIMUMAB (IPI), NIVOLUMAB (NIVO), AND THE COMBINATION FOR NEWLY DIAGNOSED GLIOBLASTOMA (GBM) . NEURO-ONCOLOGY, 20 7-7.

cited authors

  • Gilbert, Mark; Zhang, Peixin; Sloan, Andrew; Aldape, Kenneth; Wu, Jing; Rogers, Lisa; Wen, Patrick; Barani, Igor; Iwamoto, Fabio; Raval, Raju; Voloshin, Alfredo; de Groot, John; Won, Minhee; Mehta, Minesh P

authors

date/time interval

  • November 14, 2018 -

publication date

  • November 1, 2018

webpage

published in

keywords

  • Clinical Neurology
  • Life Sciences & Biomedicine
  • Neurosciences & Neurology
  • Oncology
  • Science & Technology

Location

  • New Orleans, LA

Conference

  • 23rd Annual Scientific Meeting and Education Day of the Society-for-Neuro-Oncology (SNO) / 3rd CNS Anticancer Drug Discovery and Development Conference

publisher

  • OXFORD UNIV PRESS INC

start page

  • 7

end page

  • 7

volume

  • 20